Hematologic Malignancy
High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements
CI-CAN-00009268DHLExplore in graph →
Hematologic21 active trials
- NCIt
- C125904
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009268DHLExplore in graph →
Clinical trials
31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06536049 | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 38 | Yazeed SawalhaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07649304 | AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | not yet recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 0 | Aug 13, 2026 | clinicaltrials |
| NCT05755087 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | Lapo AlinariOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04323956 | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | active not recruiting | Phase 1 | 50 | Mayo ClinicOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05908409 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies(CASSANDRA) | recruiting | Phase 1 / Phase 2 | 37 | IDP Discovery Pharma S.L.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 1 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT01742988 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | completed | Phase 1 | 106 | Curis, Inc.INDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT01897012 | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 28, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Aug 25, 2026source: clinicaltrials